Cannasat Therapeutics, Update on Patent Application for Drug Development Programs

February 27, 2008 – Cannasat Therapeutics (TSXV: CTH), the developer of novel cannabinoid-based pharmaceutical products, announced that it has received a favorable decision from the United States Patent and Trademark Office (USPTO)...
...This patent application is important for Cannasat as it is expected to form the basis for at least one of its neuropathic pain products. Neuropathic pain is associated with nerve damage and can be an especially difficult condition to treat, often requiring the use of strong narcotics that can cause serious adverse effects. This condition is caused by many common diseases such as diabetes, herpes zoster, HIV/AIDS, multiple sclerosis, and other causes of chronic pain... Cannasat Therapeutics' Press Release -

Cannasat Therapeutics, Commence Phase 1 Study of CAT 310, Potential Treatment for Neuropathic Pain

August 23, 2007 - Cannasat Therapeutics Inc. ("Cannasat") (TSX-V: CTH), announced that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310, its first cannabinoid based product that is designed to help manage neuropathic pain and other disorders... Neuropathic pain can be caused by many common diseases such as diabetes... Cannasat Therapeutics' Press Release.